ACTRN12607000214437已完成3 期
A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation
Bayer Australia Limited0 个研究点目标入组 14,269 人开始时间: 2007年4月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14,269
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Subjects must have documented atrial fibrillation on 2 separate occasions within 6 months before screening.History of prior stroke, transient ischemic attack or non-neurologic systemic embolism believed to be cardiac in origin, OR at least two of the following risk factors: heart failure, hypertension, age 75 years or greater, diabetes mellitus.
排除标准
- •Significant mitral stenosis.Transient atrial fibrillation caused by a reversible disorder.Active internal bleeding.Severe disabling stroke.History of intracranial bleeding.Haemorrhagic disorders.
研究者
相似试验
已完成
不适用
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillatio-I48 Atrial fibrillation and flutterAtrial fibrillation and flutterI48PER-025-07BAYER S.A.,
进行中（未招募）
1 期
A Study to Compare the Effect of Eprosartan versus Eprosartan Mesylate on Blood Pressure in Subjects with High Blood PresureEssential HypertensionMedDRA version: 14.1 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2010-019155-22-GBAbbott Healthcare Products B.V.596
进行中（未招募）
不适用
A Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects with High Blood PresureEUCTR2010-019155-22-DEAbbott Healthcare Products B.V.665
招募中
4 期
To Evaluate Efficacy of Lutemax 2020 (Lutein 10 mg & Zeaxanthin Isomers 2 mg) on Vision and Cognitive Performance in Healthy Children.CTRI/2022/05/042364OmniActive Health Technologies Ltd
已完成
3 期
To understand the safety and effects of Ashwagandha in healthy adults with stressCTRI/2024/03/063786OmniActive Health Technologies Limited90